Artificial intelligence, liquid and genomic biopsy to personalize the treatment of endometrial cancer and improve the prognosis Published on 03/02/2022 MD Anderson Cancer Center Foundation Spain is participating in a project, with three other European countries, that will study tumors at a molecular level and seek to expand therapy options in the most advanced stages of endometrial cancer. The study will combine pre-clinical models and artificial intelligence solutions to generate an algorithm to predict the therapeutic response of patients. Endometrial cancer is the most common gynecological tumor in developed countries and the overall survival rate of patients is reduced from 90% to 17% if there is a late diagnosis1